NUCC-390

Research use only, not for human use.

NUCC-390, a novel small-molecule CXCR4 receptor agonist, selectively induces CXCR4 receptor internalization while acting antagonistically to AMD3100.

NUCC-390 is a novel and selective small-molecule CXCR4 receptor agonist. NUCC-390 induces internalization of CXCR4 receptors and acts in an opposite way of AMD3100 (HY-10046). NUCC-390 promotes nerve recovery of function after neurodegeneration in vivo.

NUCC-390 (10 μM) produces strong (Ca)i response, but this effect can be blocked by the known potent and selective CXCR4 antagonist AMD3100.NUCC-390 (10 μM; pre-treatment 30 mins) leads to increased levels of pERK, it has the capability of stimulating signaling activity downstream of CXCR4 receptors.NUCC-390 (10 μM; 2 hours) can induce CXCR4 receptor internalization, and non-treated cells exhibit some diffuse expression of CXCR4-YFP throughout the cytosol and clear expression in the cell membrane in HEK cells.NUCC-390 (0-1.25 μM; 24 hours) boosts axonal growth in cultured cerebellar granule neurons (CGNs) via CXCR4.Western Blot Analysis Cell Line:C8161 cells?Concentration:10 μM Incubation Time:Pre-treated 30 mins Result:Increased the level of pERK.Cell Proliferation Assay Cell Line:Cerebellar granule neurons (CGNs) Concentration:0 μM; 0.0625 μM; 0.25 μM; 1.25 μM Incubation Time:24 hours Result:Stimulated axonal growth via CXCR4.

NUCC-390 (hind limb injection; 3.2 mg/kg; twice daily; 3 days) contributes to the functional and anatomical recovery of the neuromuscular junction (NMJ) following an acute nerve terminal damage by α-LTx in CD-1 mice.Animal Model:Six to eight-week-old CD1 mice Dosage:3.2 mg/kg Administration:Hind limb injection; twice daily; 3 days Result:Promoted functional and anatomical recovery of the NMJ.

——

Autophagy

CXCR

CXCR

——

——

1060524-97-1

395.54

C23H33N5O

>98% (HPLC)

——

C(=O)(C=1C2=C(N(CCC)N1)CCC(NCCC=3C=CN=CC3)C2)N4CCCCC4

——

(-20℃)

With Ice Pack

≥ 2 years